Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
|
Title: Wales General Ophthalmic Services signed orders formulary Status: Consultation completed Remit: The aim of this document is to agree an approved list of eye preparations (medicines and devices) for inclusion on the WGOS signed orders formulary. Estimated publication date: January 2026 |
|
Title: All Wales self-administration of medicines framework Status: Consultation completed Remit: The self-administration of medicines framework aims to ensure that patients who self-administer their medicines at home can do so safely during hospital admissions. Estimated publication date: December 2025 - February 2026 |
|
Title: All Wales HIV-1 Antiretroviral Prescribing Guidelines Status: Consultation completed Remit: The All Wales HIV-1 antiretroviral prescribing guideline aims to support clinicians and other healthcare professionals in the pharmacological management of HIV-1 to deliver good prescribing practice, optimise treatment to suppress the viral load while minimising the risk of adverse effects, and improve the person’s health-related quality of life. Estimated publication date: March 2026 - May 2026 |
|
Title: History-based penicillin allergy de-labelling Status: Consultation open Remit: The History-based penicillin allergy de-labelling guideline aims to support healthcare professionals to review patients with a penicillin allergy label appropriately and ensure a consistent all Wales approach. This guidance is relevant to all registered healthcare professionals and is for reviewing people, in primary care and other settings, with very low risk of true penicillin allergy and who do not require oral challenge for de-labelling. Estimated publication date: March 2026 - May 2026 |
|
Title: All Wales guidance for medicines training and education - for support workers in health and social care Status: Consultation open Remit: This guidance has been developed through collaboration with partners in both health and social care and aims to provide a framework for planning and delivering training and education to ensure people are supported to take their medicines safely and effectively. Estimated publication date: March 2026 - May 2026 |
|
Medicine name: capsaicin (Qutenza®) Reference number: 2889 Indication: Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain. Licence status: Licensed AWMSG Scrutiny Panel meeting date: 18/12/2025 |
|
Medicine name: testosterone (AndroFeme®) Reference number: 921 Indication: treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women on optimised hormone replacement therapy (HRT) Licence status: Licensed AWMSG Scrutiny Panel meeting date: 18/12/2025 |
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
|
Medicine name: infliximab Reference number: OW34 Indication: Treatment of immune checkpoint inhibitor (ICI) induced grade 3-4 pneumonitis, where symptoms have not responded to first line immunosuppression with corticosteroids Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 01/11/2025 OWMAG date: 08/12/2025 AWMSG date: 11/02/2026 |
|
Medicine name: nivolumab (Opdivo®) + ipilimumab (Yervoy®) Reference number: OW35 Indication: Neoadjuvant treatment for patients with resectable macroscopic stage III melanoma with ≥1 pathologically proven lymph node metastasis and up to 3 in-transit metastases Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 01/01/2026 OWMAG date: 09/02/2026 AWMSG date: 11/03/2026 |
|
Title: AWMSG annual report 2025-2026 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2025 and March 2026. Estimated publication date: September 2026 |
|
Title: IPFR annual report 2025-2026 Summary: Review of Individual Patient Funding Request activity in Wales between April 2025 and March 2026. Estimated publication date: November 2026 |